tiprankstipranks
Lexaria Bioscience Launches Innovative Drug Study
Company Announcements

Lexaria Bioscience Launches Innovative Drug Study

Story Highlights

Lexaria Bioscience (LEXX) has released an update.

Pick the best stocks and maximize your portfolio:

Lexaria Bioscience has initiated a groundbreaking study to explore the biodistribution of its DehydraTECH-semaglutide formulation using fluorescent imaging in rodents. This research aims to determine whether Lexaria’s technology enhances the effectiveness and safety profile of semaglutide compared to standard oral formulations.

For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyLexaria Bioscience’s Phase 1b study starts patient dosing, says H.C. Wainwright
TipRanks Canadian Auto-Generated NewsdeskLexaria Bioscience Initiates Promising Drug Study
TheFlyLexaria Bioscience begins dosing for GLP-1 study #4
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App